Treace Medical Reports $9.4M Q4 Loss, Guides $200M–$212M 2026 Revenue
Treace Medical Concepts reported a Q4 2025 net loss of $9.4 million, compared with a $0.5 million loss in Q4 2024, as revenue fell 9% due to lower-priced product mix. The company holds $48.4 million in cash and forecasts 2026 revenue of $200 million to $212 million.
1. Q4 2025 Financial Results
Treace Medical posted a net loss of $9.4 million in Q4 2025 versus $0.5 million in Q4 2024, as revenue declined 9% year-over-year driven by a shift toward lower-priced products.
2. Balance Sheet Strength and 2026 Guidance
The company ended 2025 with $48.4 million in cash, cash equivalents and marketable securities, and it expects 2026 revenue of $200 million to $212 million alongside an adjusted EBITDA loss of $4 million to $6 million.
3. Market Dynamics and Product Outlook
Management highlighted that over 25% of its surgeon base has adopted the new bunion systems, reflecting market share gains, and anticipates that launches of the Super Bite screw and Speed XM fusion system will drive case volumes and higher average selling prices later in 2026. Expansion of the biologics portfolio is expected to add revenue without diluting margins.